Hyperglycemia and microRNAs in prostate cancer.

Autor: Russo V; Regional Laboratory of Cancer Prevention, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), 50139, Florence, Italy., Tamburrino L; Andrology, Women's Endocrinology and Gender Incongruence Unit, Center for Prevention, Diagnosis and Treatment of Infertility, Careggi University Hospital, 50139, Florence, Italy., Morselli S; Department of Urology, Hesperia Hospital, 41125, Modena, Italy.; Centro Urologico Europeo (CUrE), 41125, Modena, Italy.; Unit of Urological Robotic Surgery and Renal Transplantation, Careggi University Hospital, 50139, Florence, Italy., Sani C; Regional Laboratory of Cancer Prevention, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), 50139, Florence, Italy., Baldi E; Andrology, Women's Endocrinology and Gender Incongruence Unit, Center for Prevention, Diagnosis and Treatment of Infertility, Careggi University Hospital, 50139, Florence, Italy.; Department of Experimental and Clinical Medicine, University of Florence, 50139, Florence, Italy., Sebastianelli A; Unit of Urological Robotic Surgery and Renal Transplantation, Careggi University Hospital, 50139, Florence, Italy.; Department of Experimental and Clinical Medicine, University of Florence, 50139, Florence, Italy., Raspollini MR; Department of Experimental and Clinical Medicine, University of Florence, 50139, Florence, Italy.; Department of Histopathology and Molecular Diagnostics, Careggi University Hospital, 50139, Florence, Italy., Mongia A; Regional Laboratory of Cancer Prevention, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), 50139, Florence, Italy., Carradori V; Regional Laboratory of Cancer Prevention, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), 50139, Florence, Italy., Lallo E; Regional Laboratory of Cancer Prevention, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), 50139, Florence, Italy., Munnia A; Regional Laboratory of Cancer Prevention, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), 50139, Florence, Italy., Bisanzi S; Regional Laboratory of Cancer Prevention, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), 50139, Florence, Italy., Marchiani S; Andrology, Women's Endocrinology and Gender Incongruence Unit, Center for Prevention, Diagnosis and Treatment of Infertility, Careggi University Hospital, 50139, Florence, Italy.; Department of Clinical and Experimental Biomedical Sciences 'Mario Serio', University of Florence, 50139, Florence, Italy., Visioli C; Division of Epidemiology and Clinical Governance, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), 50139, Florence, Italy., Rapi S; Clinical Chemistry Laboratory Unit, S. Luca Hospital, USL Toscana Nord Ovest, 55100, Lucca, Italy., Serni S; Unit of Urological Robotic Surgery and Renal Transplantation, Careggi University Hospital, 50139, Florence, Italy.; Department of Experimental and Clinical Medicine, University of Florence, 50139, Florence, Italy., Zappa M; Retired, formerly at Institute for Cancer Research, Prevention and Clinical Network (ISPRO), 50139, Florence, Italy., Carozzi F; Retired, formerly at Institute for Cancer Research, Prevention and Clinical Network (ISPRO), 50139, Florence, Italy., Peluso M; Regional Laboratory of Cancer Prevention, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), 50139, Florence, Italy. m.peluso@ispro.toscana.it.
Jazyk: angličtina
Zdroj: Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2024 Feb 24. Date of Electronic Publication: 2024 Feb 24.
DOI: 10.1038/s41391-024-00809-z
Abstrakt: Background: Hyperglycemia can promote the development of prostate cancer (PCa). Differential expression levels of miRNAs between PCa patients and controls were also reported. Therefore, we examined the relationship between hyperglycemia and miRNA levels in PCa.
Methods: Relative expression of urinary miR-574-3p, miR-375, miR-205-5p, miR-200b-3p, miR-187-3p, miR-182-5p, and miR-100-5p were investigated in 105 PCa patients and 138 noncancer controls by Real-Time quantitative PCR. Fasting plasma glucose measurements were retrieved from clinical records. The differential miRNA expressions among groups were compared using non-parametric tests. Correlations with glucose and prostate-specific antigen (PSA) were tested using Pearson correlation coefficient.
Results: When we analyzed miRNA expression according to glycemic state, significant down-regulations were found for miR-200b-3p, miR-187-3p, miR-182-5p, and miR-100-5p in noncancer controls with high glucose. The lowest down-regulations were observed for miR-187-3p, miR-182-5p, and miR-100-5p. Subsequently, when hyperglycemia was considered in PCa, significant dysregulations of selected miRNAs were found in hyperglycemic PCa patients than in controls with high glucose. In particular, miR-375 and miR-182-5p showed a 3-FC in hyperglycemic PCa patients than controls who left hyperglycemia untreated. Conversely, only a down-regulation of miR-574-3p was observed in PCa patients regardless of glycemic status and only modest down-regulation of miR-574-3p, miR-200b-3p, miR-187-3p and miR-182-5p were found in normoglycemic PCa patients. Next, significant correlations between miRNAs and glucose (miR-200b-3p, miR-100-5p) and PSA (miR-205-5p and miR-187-3p) were detected in controls. Similarly, miR-205-5p and miR-187-3p were correlated with glucose in PCa patients, while miR-574-3p and miR-375 showed inverse relationships.
Conclusions: miRNA dysregulations can occur in hyperglycemic PCa patients as compared to noncancer controls who left hyperglycemia untreated. Hyperglycemia can consistently promote the expression of miR-375 and miR-182-5p. Uncontrolled hyperglycemic state could contribute to the creation of a suitable microenvironment for later PCa development by promoting gene expression.
(© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: